TNF-α secretion and apoptosis of lymphocytes mediated by gene transfer

Cytokines, Cellular and Molecular Therapy

Volumn 5, Issue 3, 1999, Pages 165-173

  Ebert, Oliver ^a   Röpke, Gabriele ^b   Märten, Angela ^b   Lefterova, Petja ^b   Micka, Bettina ^b   Buttgereit, Peter ^b   Niemitz, Sigrun ^a   Trojaneck, Beate ^a   Schmidt Wolf, Gabriele ^a   Huhn, Dieter ^a   Wittig, Burghardt ^d   Schmidt Wolf, Ingo G H ^a,b,c  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d NONE

Author keywords

Apoptosis; Gene therapy; Gene transfer; Lymphocytes; TNF

Indexed keywords

FAS ANTIGEN; LYMPHOCYTE RECEPTOR; MONOCLONAL ANTIBODY CD3; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VIRUS VECTOR;

APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; ELECTROPORATION; FLOW CYTOMETRY; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; RETROVIRUS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; APOPTOSIS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE TRANSFER TECHNIQUES; HUMANS; LYMPHOCYTES; NECROSIS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0344563434     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Lanier LL, Le AM, Civin, CI et al, The relationship of CD 16 and Leu-19 antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol (1986) 136: 4480-6.
2. Smyth MJ, Norihisa Y, Ortaldo JR, Multiple cytolytic mechanisms displayed by activated human peripheral blood T cell subsets. J Immunol (1992) 148: 55-62.
3. Mehta BA, Schmidt-Wolf IGH, Weissman IL, Negrin RS, Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ and CD56+ killer cells. Blood (1995) 86: 3493-9.
4. Schmidt-Wolf IGH, Lefterova P, Johnston V et al, Propagation of large numbers of T cells with natural killer cells markers. Br J Haematol (1994) 87: 453-8.
5. Lu PH, Negrin RS, A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol (1994) 153: 1687-96.
6. Csipai M, Lefterova P, Finke S et al, Effects of interleukin-7 on proliferation of tumor cells. Cancer Res Ther Control (1996) 5: 11-16.
7. Finke S, Trojaneck B, Lefterova P, et al, Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene. Gene Ther (1998) 5: 31-9.
8. Schmidt-Wolf G, Schmidt-Wolf IGH, Cytokines and clinical gene therapy. Eur J Immunol (1995) 25: 1137-40.
9. Cotton M, Baker A, Saltik M et al, Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary cells in the presence of adenovirus. Gene Ther (1994) 1: 1-8.
10. Fallaux FJ, Kranenburg O, Cramer SJ et al, Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther (1996) 7: 215-22.
11. Graham FL, Prevec L, Manipulation of adenovirus vectors. Meth Mol Biol (1991) 7: 109-28.
12. Armant M, Delespesse G, Sarfati M, IL-2 and IL-7 but not IL-12 protect natural killer cells from death by apoptosis and up-regulate bcl-2 expression. Immunology (1995) 85: 331-7.
13. Naume B, Gately M, Espevik T, A comparative study of IL-12-, IL-2- and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. J Immunol (1992) 148: 2429-36.
14. Tos AG, Cignetti A, Rovrea G, Foa R, Retroviral vector-mediated transfer of the tumor necrosis factor alpha gene into human cancer cells restores an apoptotic cell death program and induces a bystander-killing effect. Blood (1996) 87: 2486-95.
15. Treisman J, Hwu P, Yannelli JR et al, Upregulation of tumor necrosis factor-alpha production by retrovirally transduced human tumor-infiltrating lymphocytes using trans-retinoic acid. Cell Immunol (1994) 156: 448-57.
16. Goldfeld AE, Flemington EK, Boussiotis VA et al, Calcineurin mediates human tumor necrosis factor alpha gene induction in stimulated T and B cells. Proc Natl Acad Sci USA (1992) 89: 12198-201.
17. Goldfeld AE, Tsai E, Kincaid R et al, TNF-alpha gene transcription is rapidly induced by anti-immunoglobulin and blocked by cyclosporine A and FK506 in human B cells. J Exp Med (1994) 180: 763-8.
18. Tsai EY, Jain J, Pesavento P, Rao A, Goldfeld AE, TNF alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Cell Biol (1996) 16: 459-67.
19. Bergamaschi G, Carlo-Stella C, Cazzola M et al, TNF alpha down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with AML. Leukemia (1990) 4: 426-30.
20. Koo AS, Chiu R, Soong J et al, The expression of C-jun and junB mRNA in renal cell cancer and in vitro regulation by TGF beta 1 and TNF alpha 1. J Urol (1992) 148: 1314-18.
21. Manchester KM, Heston WD, Donner DB, Tumor necrosis factor-induced cytotoxicity is accompanied by intracellular mitogenic signals in ME-180 human cervical carcinoma cells. Biochem J (1993) 290: 185-90.
22. Khoury E, Andre C, Pontvert Delucq S et al, Tumor necrosis factor alpha (TNF-α) down regulates c-kit proto-oncogene product expression in normal and acute-myeloid leukemia CD34+ cells via p55 TNF-α receptors. Blood (1994) 84: 2506-14.
23. Rosenberg SA, Young JC, Topalian SL et al, Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose holus interleukin 2. JAMA (1994) 271: 907-13.
24. Sparano JA, Fisher RI, Sunderland M et al, Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alpha 2a in patients with advanced melanoma. J Clin Oncol (1993) 11: 1969-77.
25. Buschle M, Cotton M, Kirlappos H et al, Receptor-mediated gene transfer into human T lymphocytes via binding DNA/CD3 antibody particles to the receptor complex. Hum Gene Ther (1995) 6: 753-61.